NASDAQ:CDXS - US1920051067 - Common Stock
CDXS gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 55 industry peers in the Life Sciences Tools & Services industry. Both the profitability and financial health of CDXS have multiple concerns. CDXS is valied quite expensively at the moment, while it does show a decent growth rate.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -47% | ||
ROE | -116.8% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 77.61% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.71 | ||
Debt/FCF | N/A | ||
Altman-Z | -4.77 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 5.82 | ||
Quick Ratio | 5.7 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
2.42
0 (0%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 3.82 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 3.93 | ||
P/tB | 4.11 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -47% | ||
ROE | -116.8% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 77.61% | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.71 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 68.3% | ||
Cap/Sales | 11.46% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 5.82 | ||
Quick Ratio | 5.7 | ||
Altman-Z | -4.77 |